Abstract

Precision medicine aims to empower clinicians to predict the most appropriate course of action for patients with complex diseases like cancer, diabetes, cardiomyopathy, and COVID-19. With a progressive interpretation of the clinical, molecular, and genomic factors at play in diseases, more effective and personalized medical treatments are anticipated for many disorders. Understanding patient’s metabolomics and genetic make-up in conjunction with clinical data will significantly lead to determining predisposition, diagnostic, prognostic, and predictive biomarkers and paths ultimately providing optimal and personalized care for diverse, and targeted chronic and acute diseases. In clinical settings, we need to timely model clinical and multi-omics data to find statistical patterns across millions of features to identify underlying biologic pathways, modifiable risk factors, and actionable information that support early detection and prevention of complex disorders, and development of new therapies for better patient care. It is important to calculate quantitative phenotype measurements, evaluate variants in unique genes and interpret using ACMG guidelines, find frequency of pathogenic and likely pathogenic variants without disease indicators, and observe autosomal recessive carriers with a phenotype manifestation in metabolome. Next, ensuring security to reconcile noise, we need to build and train machine-learning prognostic models to meaningfully process multisource heterogeneous data to identify high-risk rare variants and make medically relevant predictions. The goal, today, is to facilitate implementation of mainstream precision medicine to improve the traditional symptom-driven practice of medicine, and allow earlier interventions using predictive diagnostics and tailoring better-personalized treatments. We strongly recommend automated implementation of cutting-edge technologies, utilizing machine learning (ML) and artificial intelligence (AI) approaches for the multimodal data aggregation, multifactor examination, development of knowledgebase of clinical predictors for decision support, and best strategies for dealing with relevant ethical issues.

Highlights

  • Since the beginning of scientific discoveries, it has been central to understand the cause of disease and senescence [1]

  • To identify and help patients with known diseases and symptoms, and those heading toward late stages of novel infectious (e.g., COVID-19), chronic, acute, and complex diseases, it is essential to provide timely personalized treatment [2,3,4,5,6,7,8,9,10]

  • Intelligent big data platforms are necessary to improve the quality of care-delivery process by increasing permeation of electronic health record (EHR) systems into clinical environments, focusing on predictive diagnosis, enabling realtime telemedicine, and precise treatment resulting in lower spending on life-threatening complex and chronic diseases [15]

Read more

Summary

Introduction

Since the beginning of scientific discoveries, it has been central to understand the cause of disease and senescence [1]. We hypothesize that on-demand access and analysis of clinical, genetic, and metabolic data will align biomarker identification with treatment windows necessary for real-time personalized care and enhance prediction of potential disease risks [11].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.